Document is current
Any future updates will be listed below
-
Authors
Quarta, Carmelo https://orcid.org/0000-0002-1352-4239
Stemmer, Kerstin
Novikoff, Aaron https://orcid.org/0000-0002-4838-001X
Yang, Bin https://orcid.org/0000-0003-1180-6184
Klingelhuber, Felix
Harger, Alex
Bakhti, Mostafa https://orcid.org/0000-0002-2307-1122
Bastidas-Ponce, Aimee
Baugé, Eric
Campbell, Jonathan E.
Capozzi, Megan
Clemmensen, Christoffer https://orcid.org/0000-0003-2456-9667
Collden, Gustav
Cota, Perla
Douros, Jon
Drucker, Daniel J. https://orcid.org/0000-0001-6688-8127
DuBois, Barent
Feuchtinger, Annette
Garcia-Caceres, Cristina https://orcid.org/0000-0001-6376-9448
Grandl, Gerald
Hennuyer, Nathalie
Herzig, Stephan https://orcid.org/0000-0003-3950-3652
Hofmann, Susanna M. https://orcid.org/0000-0001-7682-5840
Knerr, Patrick J.
Kulaj, Konxhe
Lalloyer, Fanny
Lickert, Heiko https://orcid.org/0000-0002-4597-8825
Liskiewicz, Arek https://orcid.org/0000-0002-4102-5373
Liskiewicz, Daniela https://orcid.org/0000-0002-5859-6316
Maity, Gandhari
Perez-Tilve, Diego https://orcid.org/0000-0002-0351-4133
Prakash, Sneha
Sanchez-Garrido, Miguel A.
Zhang, Qian
Staels, Bart https://orcid.org/0000-0002-3784-1503
Krahmer, Natalie
DiMarchi, Richard D. https://orcid.org/0000-0003-0220-4085
Tschöp, Matthias H. https://orcid.org/0000-0002-4744-371X
Finan, Brian https://orcid.org/0000-0002-6467-0447
Müller, Timo D. https://orcid.org/0000-0002-0624-9339
- License Information
-
More Information
Article History
Received: 15 November 2021
Accepted: 12 July 2022
First Online: 22 August 2022
Competing interests
: M.H.T. is a member of the scientific advisory board of ERX Pharmaceuticals. He was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. He attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. He received funding for his research projects by Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He was a consultant for Bionorica SE (2013–2017), Menarini Ricerche S.p.A. (2016), and Bayer Pharma AG Berlin (2016). As former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018), and since 2018, as CEO of Helmholtz Zentrum München, he has been responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide, including but not limited to pharmaceutical corporations such as Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen and others. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes related patent portfolios of Helmholtz Zentrum München as, for example, WO/2016/188932 A2 or WO/2017/194499 A1. M.H.T. confirms that to the best of his knowledge none of the above funding sources were involved in the preparation of this paper. T.D.M. and K.S. receive research funding by Novo Nordisk. J.E.C. receives research funding from Novo Nordisk and Eli Lilly. D.J.D. has received speaking or consulting fees from Altimmune, Amgen, Eli Lilly, Kallyope, Merck, Novo Nordisk Inc. and Pfizer Inc. Mt. Sinai Hospital receives funding for preclinical studies in the Drucker laboratory from Novo Nordisk and Pfizer Inc. RDDiM is a coinventor on intellectual property owned by Indiana University and licensed to Novo Nordisk. He was previously employed by Novo Nordisk. B.F., B.Y., P.J.K., J.D. and B.D.B. are current employees of Novo Nordisk. The remaining authors declare no competing interests.
